rs121913487
|
|
|
0.800 |
GeneticVariation |
UNIPROT |
|
|
|
rs121913488
|
|
|
0.740 |
GeneticVariation |
BEFREE |
The FLT3 receptor tyrosine kinase plays an integral role in hematopoiesis, and one third of AML diagnoses exhibit gain-of-function mutations in FLT3, with the juxtamembrane domain internal tandem duplication (ITD) and the kinase domain D835Y variants observed most frequently.
|
30541869 |
2019 |
rs121913488
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Retroviral expression of FLT3-N676K in myeloid 32D cells induced AML in syngeneic C3H/HeJ mice (n = 11/13, median latency 58 days), with a transforming activity similar to FLT3-internal tandem duplication (ITD) (n = 8/8), FLT3-TKD D835Y (n = 8/9), and FLT3-ITD-N676K (n = 9/9) mutations.
|
26891877 |
2016 |
rs121913488
|
|
|
0.740 |
GeneticVariation |
BEFREE |
In addition, crenolanib inhibited drug-resistant AML primary blasts with FLT3-ITD and D835H/Y mutations.
|
24046014 |
2013 |
rs121913488
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Our FLT3-Aurora kinase inhibitor, CCT137690, successfully inhibited growth of FLT3-ITD-D835Y cells in vitro and in vivo, suggesting that dual FLT3-Aurora inhibition may overcome selective FLT3 inhibitor resistance, in part due to inhibition of Aurora kinase, and may benefit patients with FLT3-mutated AML.
|
22354205 |
2012 |
rs1057519766
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Gene expression analysis of AML patients with CBFB/MYH11 rearrangement and FLT3 N676K mutation showed a trend toward a specific expression profile.
|
23878140 |
2013 |
rs1057519766
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Moreover, further experiments investigating molecular mechanisms for leukemogenesis induced by FLT3-N676K mutation and clinical evaluation of FLT3 inhibitors in FLT3-N676K-positive AML seem warranted.
|
26891877 |
2016 |
rs1057519766
|
|
C |
0.720 |
GeneticVariation |
CLINVAR |
Gene expression analysis of AML patients with CBFB/MYH11 rearrangement and FLT3 N676K mutation showed a trend toward a specific expression profile.
|
23878140 |
2013 |
rs1057519766
|
|
T |
0.720 |
GeneticVariation |
CLINVAR |
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
|
24619500 |
2014 |
rs1057519766
|
|
T |
0.720 |
GeneticVariation |
CLINVAR |
Gene expression analysis of AML patients with CBFB/MYH11 rearrangement and FLT3 N676K mutation showed a trend toward a specific expression profile.
|
23878140 |
2013 |
rs1057519766
|
|
C |
0.720 |
GeneticVariation |
CLINVAR |
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
|
24619500 |
2014 |
rs1057519764
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Targeted next-generation sequencing at the time of AML progression on gilteritinib identified treatment-emergent mutations that activate RAS/MAPK pathway signaling, most commonly in <i>NRAS</i> or <i>KRAS.</i> Less frequently, secondary <i>FLT3</i>-F691L gatekeeper mutations or <i>BCR-ABL1</i> fusions were identified at progression.
|
31088841 |
2019 |
rs1057519764
|
|
T |
0.710 |
GeneticVariation |
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |
rs1057519764
|
|
C |
0.710 |
GeneticVariation |
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |
rs1057520026
|
|
G |
0.710 |
GeneticVariation |
CLINVAR |
The other novel mutation, FLT3 K663Q, is the first AML-associated gain-of-function mutation located outside the JM and AL domains.
|
16990784 |
2006 |
rs1057520026
|
|
|
0.710 |
GeneticVariation |
BEFREE |
The other novel mutation, FLT3 K663Q, is the first AML-associated gain-of-function mutation located outside the JM and AL domains.
|
16990784 |
2006 |
rs121913232
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Recently, novel mutations within the activation loop were identified in patients with AML: deletion of isoleucine 836 (Ile836del) and an exchange of isoleucine 836 to methionine plus an arginine insertion (Ile836Met+Arg).
|
12663439 |
2003 |
rs376588714
|
|
C |
0.710 |
GeneticVariation |
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
rs376588714
|
|
C |
0.710 |
GeneticVariation |
CLINVAR |
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
|
24619500 |
2014 |
rs376588714
|
|
C |
0.710 |
GeneticVariation |
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |
rs376588714
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
|
15345593 |
2005 |
rs1057519726
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient.
|
16371029 |
2006 |
rs1057519726
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations.
|
16573742 |
2006 |
rs1057519762
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
|
23430109 |
2013 |
rs1057519762
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
|
22504184 |
2012 |